Alim Yakubov / Shutterstock.com
The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
HIV, PrEP4All, Gilead Sciences, COVID-19, Truvada, PrEP, pre-exposure prophylaxis, patent, remdesivir, NYU, Technology Law & Policy Clinic
